Edition:
United Kingdom

Trovagene Inc (TROV.OQ)

TROV.OQ on NASDAQ Stock Exchange Capital Market

0.81USD
21 Sep 2018
Change (% chg)

$-0.01 (-1.78%)
Prev Close
$0.82
Open
$0.82
Day's High
$0.82
Day's Low
$0.81
Volume
48,458
Avg. Vol
148,100
52-wk High
$12.96
52-wk Low
$0.65

Chart for

About

Trovagene, Inc. is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more... (more)

Overall

Beta: 0.37
Market Cap(Mil.): $31.68
Shares Outstanding(Mil.): 37.27
Dividend: --
Yield (%): --

Financials

  TROV.OQ Industry Sector
P/E (TTM): -- 32.30 32.76
EPS (TTM): -1.20 -- --
ROI: -144.44 13.94 14.61
ROE: -204.02 16.79 16.33

BRIEF-Trovagene Files For Offering Of Up To $15 Mln Of Class A Units Of Common Stock And Up To $15 Mln Of Class B Units Of Common Stock

* TROVAGENE INC FILES FOR OFFERING OF UP TO $15.0 MILLION OF CLASS A UNITS OF COMMON STOCK AND UP TO $15.0 MILLION OF CLASS B UNITS OF COMMON STOCK - SEC FILING Source text: [https://bit.ly/2rAnkbg] Further company coverage:

10 May 2018

BRIEF-Trovagene Reports Q1 Loss Per Share $0.09

* TROVAGENE ANNOUNCES FIRST QUARTER 2018 HIGHLIGHTS AND FINANCIAL RESULTS

08 May 2018

Earnings vs. Estimates